US OptionsDetailed Quotes
LNTH250516C100000
- 9.54
- -0.06-0.63%
15min DelayClose Apr 28 16:00 ET
9.54High9.00Low
9.10Open9.60Pre Close2.35K Volume83 Open Interest100.00Strike Price2.12MTurnover96.15%IV6.66%PremiumMay 16, 2025Expiry Date2.70Intrinsic Value100Multiplier17DDays to Expiry6.84Extrinsic Value100Contract SizeAmericanOptions Type0.5953Delta0.0178Gamma10.22Leverage Ratio-0.2477Theta0.0247Rho6.08Eff Leverage0.0875Vega
Lantheus Stock Discussion
Sign in to post a comment
$Lantheus (LNTH.US)$
Lantheus Holdings is a specialty radiopharmaceutical company trading around $80 per share. I am bullish.
Fair Value Estimations
A discounted cash flow (DCF) model values LNTH at $99.48 per share, based on a 10% discount rate and moderating FCF growth.
A reverse DCF suggests the market is pricing in just 7% annual FCF growth, despite historical FCF growth of ~50%.
A relative P/E analysis (15x-20x forward earnings) supports a fair v...
Lantheus Holdings is a specialty radiopharmaceutical company trading around $80 per share. I am bullish.
Fair Value Estimations
A discounted cash flow (DCF) model values LNTH at $99.48 per share, based on a 10% discount rate and moderating FCF growth.
A reverse DCF suggests the market is pricing in just 7% annual FCF growth, despite historical FCF growth of ~50%.
A relative P/E analysis (15x-20x forward earnings) supports a fair v...
2
1
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
$Lantheus (LNTH.US)$
Revolutionary Prostate Cancer Detection Breakthrough: Lantheus PYLARIFY Shows Success in Low PSA Patients
Revolutionary Prostate Cancer Detection Breakthrough: Lantheus PYLARIFY Shows Success in Low PSA Patients
$Lantheus (LNTH.US)$ lets go! 🚀🚀🚀🚀
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? ![]()
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...
2
2
$Lantheus (LNTH.US)$ someone knows something
4
$Lantheus (LNTH.US)$ what happened
1
$Cassava Sciences (SAVA.US)$ : “If they can have something big, that stock triples. If they don’t, I think it drifts down. I like that risk/reward, but understand it’s speculative.”
$Lantheus (LNTH.US)$ : “I think it’s great..Lantheus is terrific.”
$Lantheus (LNTH.US)$ : “I think it’s great..Lantheus is terrific.”
$Lantheus (LNTH.US)$ let’s go baby!
Last week’s PDUFAs:
$BeiGene (BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb (BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals (VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia (EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$BeiGene (BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb (BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals (VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia (EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
22
2
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
thoughtful Bat_8163 : i have noticed this company 6 years ago as it merges with Progenics, one of my holdings. Amazing development!